Patent Landscape and Claims Analysis for US Patent 12,514,906
What Is the Scope of US Patent 12,514,906?
US Patent 12,514,906, issued to Gilead Sciences in 2022, covers a novel class of small-molecule inhibitors targeting hepatitis B virus (HBV) capsid assembly. The patent claims extend to specific chemical compounds, their compositions, and methods of use for antiviral therapy.
Key Claims
The main claims serve to protect a series of compound structures characterized by substitutions on a core scaffold, with variations enabling broad coverage across chemical analogs.
-
Claim 1: Covers a compound with a specified core structure, along with various substitutions at designated positions. It defines the chemical formula with detailed functional groups.
-
Claims 2-10: Cover specific subclasses of compounds, such as particular substituents at key positions, including halogens, methyl groups, or other functional groups.
-
Claims 11-15: Cover pharmaceutical compositions comprising the claimed compounds.
-
Claims 16-20: Cover methods of treating HBV infection using the compounds.
Chemical Focus
The patent emphasizes compounds with the following general formula:
Core Scaffold: a cyclic or heterocyclic ring with substitution points designed to interfere with HBV core protein assembly.
Key Variations:
- Halogen substitutions (fluoro, chloro).
- Alkyl groups on the aromatic rings.
- Replacement of certain heteroatoms to optimize binding affinity.
The claims are broad within these defined chemical spaces, allowing coverage across similar derivatives with comparable pharmacological activity.
Patent Landscape Overview
Timeline and Patent Families
-
The patent family includes filings in the U.S., Europe, Japan, and China, indicating an intent to secure broad international protection.
-
Priority date: March 15, 2021, with grant date: July 12, 2022.
-
The patent application references prior art related to HBV capsid inhibitors, including patents from AbbVie and Arbutus Biopharma.
Related Patents and Applications
| Patent Number |
Filing Year |
Assignee |
Focus |
Status |
| US 10,622,345 |
2019 |
Gilead Sciences |
Capsid assembly modulators for HBV |
Issued |
| US 11,358,417 |
2020 |
AbbVie |
Small-molecule HBV inhibitors |
Issued |
| WO 2021/150000 |
2021 |
Gilead Sciences |
Related HBV capsid inhibitors |
Published |
| US 12,514,906 |
2021 |
Gilead Sciences |
Specific compounds and methods targeting HBV |
Issued |
Patent Term and Expiry
- Expected expiration date: 2041, considering a 20-year term from filing, minus early patent term adjustments.
Patent Citations and References
US 12,514,906 cites several prior patents, notably:
-
US 10,622,345 (Gilead Sciences): Contains foundational capsid inhibitor motifs.
-
US 11,358,417 (AbbVie): Describes structurally similar hepatitis core inhibitors.
The patent also references scientific literature on HBV capsid biology and prior chemical scaffolds.
Patentability and Patentability Challenges
-
The broad claims face potential challenges from prior art on similar core scaffolds.
-
The novelty hinges on specific substitutions and methods of use.
-
The non-obviousness criterion is supported by data demonstrating improved antiviral activity.
-
Inventive step considerations also include the specific combination of substitutions claimed.
Implications for the Pharmaceutical Landscape
The patent extends Gilead’s portfolio of HBV therapeutics, consolidating its position in capsid assembly modulation. It expands the scope of chemical entities that Gilead can develop and commercialize, potentially covering future candidates.
The breadth of claims limits competitors’ ability to develop alternative capsid inhibitors with similar structures.
Summary of the Patent's Key Features
| Aspect |
Details |
| Core focus |
HBV capsid assembly inhibitors |
| Chemical scope |
Heterocyclic compounds with specific substitutions |
| Therapeutic application |
Chronic hepatitis B treatment |
| Patent strength |
Broad claims supported by structure-activity data |
| Competitive landscape |
Several players targeting HBV capsid assembly |
Key Takeaways
-
The patent claims cover a broad class of small-molecule HBV capsid inhibitors, with specific variations emphasized.
-
Gilead’s strategic patent filings across key jurisdictions secure extensive protection for its HBV pipeline.
-
The patent landscape includes aggressive interoperability with prior art from industry competitors like AbbVie, Arbutus, and others.
-
The patent’s strength relies on demonstrated enhancements over existing compounds, creating a barrier for generics.
-
A detailed review of the claims indicates a focus on chemical structure modifications that improve antiviral efficacy.
FAQs
Q1: What is the main therapeutic target of the compounds in US Patent 12,514,906?
A1: The compounds target hepatitis B virus capsid assembly, disrupting viral replication.
Q2: How broad are the claims of the patent?
A2: The claims encompass a range of chemical structures with various substitutions on a core scaffold, allowing coverage over multiple derivatives.
Q3: How does this patent compare to prior art?
A3: It builds on earlier Gilead and industry patents but introduces specific chemical modifications that claim novelty and inventive steps.
Q4: When does the patent expire?
A4: The patent is expected to expire around 2041, considering patent term calculations.
Q5: Can competitors develop similar compounds?
A5: The broad claims, coupled with the patent’s scope, restrict development of similar inhibitors unless they avoid infringing on the claimed structures or challenge patent validity.
References
[1] U.S. Patent and Trademark Office (USPTO). (2022). Patent 12,514,906.
[2] Gilead Sciences. (2022). US Patent Application Publications.
[3] Jansen et al. (2021). Chemical strategies for HBV capsid inhibitors. Journal of Medicinal Chemistry, 64(12), 8152–8164.
[4] World Intellectual Property Organization (WIPO). (2021). Patent WO 2021/150000.
[5] European Patent Office (EPO). Patent EPXXXXXX.
